These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12670538)

  • 1. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia.
    Kauppi AM; Nordfelth R; Uvell H; Wolf-Watz H; Elofsson M
    Chem Biol; 2003 Mar; 10(3):241-9. PubMed ID: 12670538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disarming the invader.
    Young GM
    Chem Biol; 2003 Mar; 10(3):204-5. PubMed ID: 12670533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule inhibitors specifically targeting type III secretion.
    Nordfelth R; Kauppi AM; Norberg HA; Wolf-Watz H; Elofsson M
    Infect Immun; 2005 May; 73(5):3104-14. PubMed ID: 15845518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An NF-κB-based high-throughput screen identifies piericidins as inhibitors of the Yersinia pseudotuberculosis type III secretion system.
    Duncan MC; Wong WR; Dupzyk AJ; Bray WM; Linington RG; Auerbuch V
    Antimicrob Agents Chemother; 2014; 58(2):1118-26. PubMed ID: 24295981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic
    Morgan JM; Lam HN; Delgado J; Luu J; Mohammadi S; Isberg RR; Wang H; Auerbuch V
    Front Cell Infect Microbiol; 2018; 8():404. PubMed ID: 30524970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of virulence factor expression by pathogen target cell contact.
    Pettersson J; Nordfelth R; Dubinina E; Bergman T; Gustafsson M; Magnusson KE; Wolf-Watz H
    Science; 1996 Aug; 273(5279):1231-3. PubMed ID: 8703058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of small-molecule inhibitors of Yop translocation in Yersinia pseudotuberculosis.
    Harmon DE; Davis AJ; Castillo C; Mecsas J
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3241-54. PubMed ID: 20498321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional conservation of the secretion and translocation machinery for virulence proteins of yersiniae, salmonellae and shigellae.
    Rosqvist R; Håkansson S; Forsberg A; Wolf-Watz H
    EMBO J; 1995 Sep; 14(17):4187-95. PubMed ID: 7556059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proinflammatory signalling stimulated by the type III translocation factor YopB is counteracted by multiple effectors in epithelial cells infected with Yersinia pseudotuberculosis.
    Viboud GI; So SS; Ryndak MB; Bliska JB
    Mol Microbiol; 2003 Mar; 47(5):1305-15. PubMed ID: 12603736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring resveratrol dimers as virulence blocking agents - Attenuation of type III secretion in Yersinia pseudotuberculosis and Pseudomonas aeruginosa.
    Sundin C; Zetterström CE; Vo DD; Brkljača R; Urban S; Elofsson M
    Sci Rep; 2020 Feb; 10(1):2103. PubMed ID: 32034212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished LcrV secretion attenuates Yersinia pseudotuberculosis virulence.
    Bröms JE; Francis MS; Forsberg A
    J Bacteriol; 2007 Dec; 189(23):8417-29. PubMed ID: 17873031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The type III secretion chaperone LcrH co-operates with YopD to establish a negative, regulatory loop for control of Yop synthesis in Yersinia pseudotuberculosis.
    Francis MS; Lloyd SA; Wolf-Watz H
    Mol Microbiol; 2001 Nov; 42(4):1075-93. PubMed ID: 11737648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RhoGAP activity of the Yersinia pseudotuberculosis cytotoxin YopE is required for antiphagocytic function and virulence.
    Black DS; Bliska JB
    Mol Microbiol; 2000 Aug; 37(3):515-27. PubMed ID: 10931345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delineation and mutational analysis of the Yersinia pseudotuberculosis YopE domains which mediate translocation across bacterial and eukaryotic cellular membranes.
    Schesser K; Frithz-Lindsten E; Wolf-Watz H
    J Bacteriol; 1996 Dec; 178(24):7227-33. PubMed ID: 8955406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model.
    Garrity-Ryan LK; Kim OK; Balada-Llasat JM; Bartlett VJ; Verma AK; Fisher ML; Castillo C; Songsungthong W; Tanaka SK; Levy SB; Mecsas J; Alekshun MN
    Infect Immun; 2010 Nov; 78(11):4683-90. PubMed ID: 20823209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of Yersinia Yop-effector delivery by translocated YopE.
    Aili M; Isaksson EL; Carlsson SE; Wolf-Watz H; Rosqvist R; Francis MS
    Int J Med Microbiol; 2008 Apr; 298(3-4):183-92. PubMed ID: 17597003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yersinia YopE is targeted for type III secretion by N-terminal, not mRNA, signals.
    Lloyd SA; Norman M; Rosqvist R; Wolf-Watz H
    Mol Microbiol; 2001 Jan; 39(2):520-31. PubMed ID: 11136471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A type III secretion system inhibitor targets YopD while revealing differential regulation of secretion in calcium-blind mutants of Yersinia pestis.
    Jessen DL; Bradley DS; Nilles ML
    Antimicrob Agents Chemother; 2014; 58(2):839-50. PubMed ID: 24247143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the Gram-negative bacterium Yersinia.
    Dahlgren MK; Zetterström CE; Gylfe S; Linusson A; Elofsson M
    Bioorg Med Chem; 2010 Apr; 18(7):2686-703. PubMed ID: 20219378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Cyclic Peptomers as Type III Secretion System Inhibitors.
    Lam H; Schwochert J; Lao Y; Lau T; Lloyd C; Luu J; Kooner O; Morgan J; Lokey S; Auerbuch V
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.